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Abstract
Background: The detection of anti-dsDNA antibodies is critical for the diagnosis and follow-up of systemic lupus
erythematosus (SLE) patients. The presently available assays are characterized by a non-optimal specificity (solid
phase assays) or sensitivity (Crithidia Luciliae immunofluorescence test (CLIFT)). To overcome the limits of CLIFT and
solid phase chromatin assays, we explored the diagnostic potential of an assay based on plasmid DNA containing a
highly bent fragment of 211 bp from Crithidia Luciliae minicircles, complexed with histone peptides.
Methods: Electrically neutral complexes of PK201/CAT plasmid (PK) DNA and histone 4 (H4) peptides were
evaluated by electromobility shift assay. Complexes of H4 peptides and PK were absorbed to the solid phase to
detect specific immunoglobulin G (IgG) in sera. Sera from 109 SLE patients, 100 normal healthy subjects, and 169
disease controls were tested.
Results: H4(14-34) containing the consensus sequence for DNA binding interacts with PK, retarding its migration.
H4(14-34)/PK complexes were used to test sera by ELISA. Anti-H4-PK antibodies were detected in 56 % of SLE sera (more
frequently in patients with skin or joint involvement) versus 5.9 % in disease controls; inhibition assays show that sera
react with epitopes present on DNA or on the complex, not on the peptide. Antibody titer is correlated with European
Consensus Lupus Activity Measurement (ECLAM) score and anti-complement component 1q (C1q) antibodies, negatively
with C3 levels. Anti-H4-PK antibodies compared with CLIFT and solid phase dsDNA assays display moderate concordance.
Conclusions: The H4/PK assay is a simple and reliable test which is useful for the differential diagnosis and evaluation of
disease activity in SLE patients.
Keywords: Anti-DNA antibodies, Systemic lupus erythematosus, Synthetic peptides, Autoantibodies, Autoimmune
diseases
Background
Anti-dsDNA antibodies react with linear and conform-
ational determinants exposed on the double helix of DNA
and cross-react with phospholipids, carbohydrates, and
proteins [1]. These autoantibodies are exclusively detected
in sera from patients affected by systemic lupus erythema-
tosus (SLE) and in animal models of the disease [2–4].
Thus, the presence in sera of anti-dsDNA antibodies is one
of the serological criteria for the diagnosis of SLE [5, 6]. It
is also well known that the titer of anti-dsDNA antibodies
fluctuates with disease activity and is related to disease
flares, especially at the renal level [7, 8]. Because of this
diagnostic and prognostic relevance, simple and reliable
assays for their detection are needed [9]. A currently used
assay for anti-dsDNA antibodies is the immunofluores-
cence test that detects immunoglobulin G (IgG) antibodies
binding the circular DNA in kinetoplasts of Crithidia
Fasciculata var. Luciliae (CLIF test) [10]. The kinetoplast
DNA has one of the highest degrees of stable curvature,
resembling nucleosomal DNA, and it has been proposed
that antibodies detected by CLIF are probably reactive with
nucleosomes in vivo [11, 12].
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It is well known that the CLIF test (CLIFT) is highly
specific for the diagnosis of SLE but poorly sensitive; posi-
tivity in the assay is fairly predictive of active disease, espe-
cially at the renal and hematological level [13, 14].
Another criticism of the CLIFT is inherent to the perform-
ance of immunofluorescent assays, which require trained
personnel and give semi-quantitative results. Because of
these limits, a number of solid phase assays for the detec-
tion of anti-dsDNA antibodies have been proposed and
commercialized. These assays differ widely for a number
of parameters, including the source of DNA (genomic or
plasmidic), the technique to absorb DNA to the solid
phase, the type of solid phase, and the detection system. In
parallel with this heterogeneity, the performance of ELISA
is variable; using normal blood donors as controls and
setting specificity at 95 %, the sensitivity can vary between
60 and 80 %. More differences are detected when sera
from patients affected by other autoimmune disorders are
evaluated. In this setting, the ability of ELISA to discri-
minate SLE from other disorders can be poor [13, 14].
Similar observations are applicable to anti-nucleosome
antibodies, a family of anti-chromatin antibodies, mea-
sured by solid phase assays using intact or H1-stripped
nucleosomes that detect antibodies reactive with DNA,
histones, or determinants formed by the association of
DNA with histones [15, 16]. Anti-nucleosome antibodies
display a sensitivity and specificity similar to solid phase
assays for anti-dsDNA antibodies, and similar correlations
with disease activity and organ involvement in SLE.
However, anti-nucleosome antibodies are detected also in
patients with other connective tissue disorders, and
namely in systemic sclerosis, mixed connective tissue
disorder, and primary anti-phospholipid syndrome [17].
Thus, they represent a valuable tool for the analysis of
SLE patients, but are not optimal in the differential diag-
nosis of SLE versus other systemic autoimmune disorders.
To overcome the limits of CLIFT and solid phase chro-
matin assays, we explored the diagnostic potential of an
assay based on plasmid DNA containing a highly bent frag-
ment of 211 bp from Crithidia Luciliae minicircles [18],
complexed with histone peptides. As the interaction of
histone 4 (H4) with DNA has been finely mapped [19, 20],
H4 peptides containing the consensus sequence for DNA
binding were selected and synthesized. A specific and
sensitive assay was obtained that detects antibodies
exclusively in SLE sera and gives complementary results
when compared with CLIFT and ELISA.
Methods
Patients
A cohort of 109 SLE patients (99 female and 10 males, aged
15–71 years, mean age 34 years) attending the Clinical
Immunology and Rheumatology Units of the University of
Pisa were included in this study. Two samples were
obtained from 16 patients (more than 1 month apart) and,
on the whole, 125 sera were analyzed.
A full clinical and serological evaluation was per-
formed that included measurement of complement
levels, anti-dsDNA, and anti-complement component
1q (C1q) antibodies. Anti-dsDNA antibodies were
detected by a commercial ELISA (Aeskulisa, Aesku
Diagnostics, Wendelsheim, Germany), according to the
manufacturer’s instructions, and by CLIFT. Anti-C1q
antibodies were detected by ELISA as previously
described [21]. On the basis of clinical and serological
findings, a disease activity score (European Consensus
Lupus Activity Measurement; ECLAM) [22] was calcu-
lated; an ECLAM score >2 was considered to be indica-
tive of active disease.
One hundred and sixty-nine patients (151 females, 18
males) affected by other systemic autoimmune disorders
were also enrolled (40 rheumatoid arthritis (RA), 30
idiopathic inflammatory myopathies (IIM) (9 polymyositis
(PM) and 6 dermatomyositis (DM)), 29 undifferentiated
connective tissue disease (UCTD), 27 Sjogren syndrome
(SjS), 29 systemic sclerosis (SSc), 5 anti-phospholipid
syndrome (APS), 4 psoriasic arthritis (PsA), 3 polymyalgia
rheumatica (PMR), and 2 systemic vasculitis). The diagno-
sis of SSc was based on the ACR criteria [23]; PsA was
diagnosed according to the criteria of Vasey and Espinoza
[24]; SjS was diagnosed according to the criteria of the
American European Consensus Group [25]; UCTD
patients were classified as stable UCTD, with a disease
duration longer than 5 years [26]; RA was diagnosed
according to ACR/EULAR criteria 2010 [27]; and PM/DM
were diagnosed according to Bohan and Peter [28].
One hundred normal healthy subjects (NHS) served as
controls. Informed consent was obtained from all the
subjects, and the study was approved by the local Ethical
Committee (protocol 3661/2012).
Peptide synthesis
Peptides were obtained by solid phase synthesis and
purified to homogeneity by semi-preparative HPLC,
according to previously reported methods optimized in
our laboratory [29]. Their sequences and some relevant
chemical properties are shown in Table 1.
Cloning of pDNA in competent Escherichia coli cells and
pDNA extraction
The high-copy PK201/CAT plasmid, a kind gift of E. Di
Mauro (University of Rome, “La Sapienza”), is 3228 base
pairs long and contains the StuI–AccI 211-bp bent segment
from the Trypanosomatidae protozoan C. fasciculata
cloned in the BamHI site of the vector pSP65 [18].
E. coli competent cells (MAX Efficiency® Stbl2™,
Invitrogen™) were transformed with plasmid DNA by
means of the heat shock procedure and selected by
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ampicillin. Pelleted bacteria were treated with the
alkaline lysis procedure to purify the pK201/CAT
plasmid DNA (pDNA) [30]. The quality of the prepar-
ation was checked by 1 % (w/v) agarose gel electrophor-
esis, and the concentration and purity assessed by
determining the A260/280 and A260/320 ratios in UV-
Vis spectrometry.
Preparation of peptide/pDNA complexes
For the pDNA/peptide complexes, histone peptides were
used at the concentration that allows the formation of
electrically neutral complexes, according to both the
negative to positive charges ratio (N/P) and the respect-
ive molar masses of the two species. Briefly, the volumes
of the plasmid and the peptides calculated according to
the desired concentrations were mixed in a sterile tube.
After an incubation for 1 h at 37 ° C, the mixture were
diluted to the final volume of coating in TBS, EDTA
10 mM (pH 7), and loaded on the plates for ELISA.
Electromobility shift assay
For the electromobility shift assay (EMSA), pK201/CAT
was linearized by EcoRI digestion. Linearized plasmid
(5 μg) was incubated with histone peptides H2B(107-125),
H4(56-71), H4(7-23), H4(31-50), H4(14-34) and its scram-
ble form, H4(21-37), MAP-Cys-[H4(14-34)], and H4(14-
22) at the previously established ratio. The amounts used
were, respectively, 2.0, 2.38, 1.85, 1.1, 1.28, 1.60, 1.98, 1.68,
1.08, and 1.60 μg, with 1.65 μg of the control FcεRIα(46-
65) peptide. After 1 h incubation at room temperature,
the mixtures were loaded on 1.0 % agarose gel in TAE
Tris-acetate-EDTA (TAE) buffer for 1.5 h along with an
equal amount of non-restricted pDNA, restricted but
non-complexed pDNA, and 2 μl 1 kb ladder (Bio Rad EZ
load 1 kb). The gel was then stained with 5 μl ethidium
bromide in 100 ml TAE buffer for 20 min. After a brief
destaining step, the ethidium bromide fluorescence signal
following UV irradiation was acquired by means of the
VersaDoc Imaging System and QuantityOne analysis
software (Bio-Rad, Hercules, CA, USA).
Detection of anti-pDNA/peptide antibodies
Anti-pDNA/peptide antibodies were detected in the sera
by ELISA. Briefly, the pPK201/CAT–H4(14-34) complex
prepared as described above was diluted in TBS-EDTA
10 mM buffer (pH 7) at the final concentrations of
20 μg/ml for the pDNA and 6.37 μg/ml for the peptide,
added to polystyrene plates (Nunc MaxiSorp F96; Nunc,
Roskilde, Denmark), and incubated overnight at 4 °C.
Saturation was carried out with PBS containing 3 % bo-
vine serum albumin (BSA) for 45 min at room
temperature. Sera diluted 1:250 (dilution offering the
best discrimination between normal and pathological
sera) in PBS containing 1 % BSA and 0.05 % Tween 20
were incubated in duplicate on the plates for 3 h at
room temperature. After washing with PBS–0.1 %
Tween, anti-human IgG alkaline phosphatase-
conjugated antibody (Sigma-Aldrich, St Louis, MO,
USA) was added to the wells, and the plates were incu-
bated for 2 h at room temperature. Alkaline phosphatase
activity was revealed with p-nitrophenyl phosphate in
50 mM Na2CO3/NaHCO3 (pH 9.6). Results were
expressed as arbitrary units on the base of calibration
curves set up by means of an internal standard.
Detection of anti-pDNA antibodies
Anti-pDNA antibodies were detected by ELISA as
previously described [31]. Briefly, polystyrene plates
(Nunc MaxiSorp F96; Nunc, Roskilde, Denmark) were
pre-coated for 1 h with polylysine 50 μg/ml, washed with
TBS, and then coated with 20 μg/ml of the pDNA in
TBS 10 mM EDTA. After overnight incubation at 4 °C,
the residual positive charges of lysine were blocked by
the addition of polyglutamate 50 μg/ml in TBS 10 mM
EDTA. The plates were again washed with TBS, and
saturation was carried out with PBS with 3 % BSA for
45 min at room temperature. Sera diluted in PBS with
1 % BSA 0.05 % Tween (diluting buffer) were incubated
in duplicate on the plates for 3 h at room temperature.
After washing with PBS–0.1 % Tween, anti-human IgG
alkaline phosphatase-conjugated antibody (Sigma-Al-
drich) was added to the wells, and the plates were
incubated for 2 h at room temperature. Alkaline phos-
phatase activity was revealed with p-nitrophenyl phos-
phate in 50 mM Na2CO3/NaHCO3 (pH 9.6). Results
Table 1 Sequences, isoelectric points (pI), and DNA consensus
sequence (written in bold) of the histone peptides used in the
study
Name Sequence pI DNA consensus
sequence
H2B(107-125) AKHAVSEGTKAVTKYTSSK 9.83 n.a.
H4(56-71) GVLKVFLENVIRDAVT 6.07 0
H4(76-91)-Gly AKRKTVTAMDVVYALKG 10.00 0
H4(7-22) GKGLGKGGAKRHRKVL 12.03 KRHRK
H4(31-50) KPAIRRLARRGGVKRISGLI 12.6 0
H4(14-34) GAKRHRKVLRDNIQGITKPAI 11.73 KRHRK
H4(21-37) VLRDNIQGITKPAIRRL 11.71 0
MAP-Cys-
[H4(14-34)]4
H4-(GAKRHRKVLRDNIQGITKPAI)
4-Lys2-Lys-bAla-Cys-OH
12.16 KRHRK
H4(14-22) GAKRHRKVL 12.02 KRHRK
Scramble
H4(14-34)
KIVPKTLHRGDNRAKQGIRAI 11.73 0
FcεRIα(46-65) SEETNSSLNIVNAKFEDSGE 3.91 Not present
H4 histone 4
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were expressed as arbitrary units on the base of calibra-
tion curves set up by means of an internal standard.
Detection of anti-dsDNA antibodies
Anti-dsDNA antibodies were detected according to manu-
facturer’s instructions by a commercially available ELISA
(Aeskulisa dsDNA IgG, Aesku Diagnostic, Wendelsheim,
Germany), based on a human recombinant dsDNA source
as antigen bound to microwells. The values were expressed
as IU/ml.
Statistical analysis
Quantitative variables were compared between groups
using Mann Whitney U test. The frequency of different
clinical parameters was compared between anti-DNA-
positive and anti-DNA-negative using the Fisher exact
test. Sensitivity and specificity were evaluated by means
of receiving operating characteristic (ROC) curves.
Correlations were determined using Spearman Rank
correlation coefficient. P < 0.05 was considered as signifi-
cant; Prism 4 for Windows (GraphPad Software Inc.)
was used for the analysis. Concordance was analyzed by
means of the Cohen K coefficient.
Results
Histone peptides interact with plasmid DNA
Since histone H4 is known to interact with DNA, we
explored the ability of H4 peptides to form complexes
with DNA. With this aim, we synthesized linear peptides
either containing or not containing the consensus
sequence KRHRK for DNA binding (Table 1), and tested
their ability to form complexes with plasmid DNA.
The H4 peptides, as well as control peptides, were
pre-incubated with pPK201/CAT DNA linearized by
EcoRI digestion, and the mix was loaded on agarose gel.
H4(14-34) and H4(7-22), but not other H4 sequences or
control peptides including a peptide of similar charge,
H2b(107-125), retarded the migration of linearized
plasmid DNA in a concentration-dependent manner
(Fig. 1a and b). H4(14-34) and H4(7-22) peptides were
thus selected for further experiments.
Peptide/DNA complexes as a probe to detect antibodies
in sera
pPK201/CAT and H4(14-34) were preincubated at 37 °C
for 1 h and then diluted in the final coating volume and
added to polystyrene plates. Sera from NHS, disease
controls (DC), and SLE patients were incubated on the
Fig. 1 Histone 4 peptides interacting with plasmid DNA. Peptides were pre-incubated with plasmid DNA, linearized by means of EcoRI digestion,
and the mix was loaded on agarose gel. The H4(14-34) and H4(14-22) peptides, but not H2b and control peptides, retard the migration of linearized
plasmid DNA (a). The H4(14-34) peptide retards the migration of plasmid DNA in a concentration-dependent manner (b). a. Lane 1: MW marker 1 Kbp;
Lane 2: pPK201/CAT, unrestricted; Lane 3: pPK201/CAT, restricted; Lane 4: restricted pPK201/CAT + H2B(107-125); Lane 5: restricted pPK201/CAT +
H4(56-71); Lane 6: restricted pPK201/CAT + H4(76-91)-Gly; Lane 7: restricted pPK201/CAT + H4(7-22); Lane 8: restricted pPK201/CAT + H4(31-50); Lane 9:
restricted pPK201/CAT + H4(14-34); Lane 10: restricted pPK201/CAT + H4(21-37); Lane 11: restricted pPK201/CAT +MAP-Cys-[H4(14-34)]4; Lane 12:
restricted pPK201/CAT + H4(14-22); Lane 13: restricted pPK201/CAT + scramble H4(14-34); Lane 14: restricted pPK201/CAT + FcεRIα(46-65). b: Lane 1:
MW markers 1 Kbp; Lane 2: PK plasmid, unrestricted; Lane 3: PK plasmid, restricted; Lane 4: PK plasmid, restricted + H4 peptide, 5 μg; Lane 5: PK plasmid,
restricted + H4 peptide, 2.5 μg; Lane 6: PK plasmid, restricted + H4 peptide, 1.25 μg; Lane 7: PK plasmid, restricted + H4 peptide, 0.625 μg
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plates coated with the peptide/plasmid complex, and the
binding was detected by anti-IgG antiserum.
The results indicate that PK201/H4(14-34) complexes
discriminate between SLE patients and NHS or DC
(Fig. 2a). In fact, 70 of 125 SLE sera contain anti-PK/H4
antibodies, as compared with 10 of 169 DC. No binding
was detected to solid phase peptide (data not shown).
On the contrary, SLE sera and also disease controls bind
to solid phase PK201/CAT (Fig. 2b). The ROC curve
confirms the better sensitivity and specificity of the assay
employing the peptide DNA complex as compared with
pDNA alone (Fig. 2c and d). Data on the binding of
disease controls to pDNA and PK201/H4(14-34) are
reported in Additional file 1 (Table S1).
In similar experiments performed with peptide
H4(7-22), a lower number of SLE sera bound to the
PK201/H4(7-22) complex compared to the PK201/
H4(14-34) (35 % versus 55 %, data not shown); thus,
further experiments were performed with H4(14-34)
only.
To better define the specificity of serum antibodies,
we performed inhibition assays by preincubating sera
with PK/H4(14-34), plasmid DNA, or H4 peptide before
transferring to PK/H4(14-34)-coated plates. In some
sera, pre-incubation with PK/H4 or PK alone similarly
inhibited the binding to solid phase PK/H4; in others, a
higher inhibition is obtained with PK/H4, indicating the
presence of antibodies preferentially reactive with the
complex. H4 peptide does not exert any inhibition.
Representative examples are given in Fig. 3. These re-
sults suggest that the epitopes recognized by serum anti-
bodies reactive in the assay reside on DNA or on the
complex, but not on the H4 peptide.
Correlation with other assays for anti-dsDNA antibody
detection
A good correlation is observed with anti-dsDNA anti-
bodies detected by Aeskulisa (Fig. 4a) but the results
obtained with the two assays are not completely overlap-
ping. If the vast majority of sera are either positive or
negative on both tests, 26 sera are reactive only with
dsDNA and 9 with PK/H4 only. Similar data are
obtained comparing the PK/H4 assay with CLIF: 28 sera
are reactive only with PK/H4 and 15 only by CLIF. The
analysis of concordance is reported in Table 2.
Fig. 2 PK/H4 as a probe to detect antibodies in sera. PK/H4 complexes or pDNA (20 μg/ml) were used to coat polystyrene plates; diluted sera were
incubated on plates and bound antibodies detected by anti-IgG antibodies. The PK/H4 complexes (a), but not the uncomplexed pDNA (b), are able to
discriminate normal healthy subjects (NHS), systemic lupus erythematosus patients (SLE), and disease controls (DC). Sensitivity and specificity evaluated
by the ROC curves are reported in c PK/H4 complex and d uncomplexed pDNA
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Anti-PK/H4 antibodies, disease activity, and disease
manifestations
The amount of IgG specific for the PK/H4 complex are
correlated with the ECLAM score (r = 0.4094, p < 0.0001;
Fig. 4b) and with anti-C1q autoantibody titers (r = 0.3106,
p = 0.0176; Fig. 4c), and inversely correlated with comple-
ment C3 levels (r = –0.4196, p < 0.0001; Fig 4d). In this co-
hort of patients, the ECLAM score is also correlated with
the amount of anti-pDNA antibodies (r = 0.51, p < 0.0001)
or anti-dsDNA antibodies detected by Aeskulisa (r = 0.51,
p < 0.0001).
The relationship between the presence and levels of anti-
PK/H4 antibodies and the most frequent manifestations of
the disease was then analyzed, in comparison with the
assays for anti-dsDNA detection. The assays were able to
detect antibodies in patients affected by arthritis or skin
involvement or nephritis differently. In fact, the mean levels
of antibodies were significantly higher in SLE patients with
nephritis and arthritis when detected by anti-dsDNA
Aeskulisa (p = 0.02 and p = 0.005, respectively), and in
patients with arthritis and skin involvement when detected
by PK/H4 (p = 0.007 and p = 0.02, respectively). Taking into
account the frequency of positive results in the different
groups, patients with skin involvement were more
frequently positive with Aeskulisa (p = 0.048), patients with
arthritis with PK/H4 (p = 0.048), and patients with nephritis
with CLIFT (p = 0.039).
Discussion
The detection of anti-dsDNA antibodies is a crucial
issue in the diagnosis of SLE, especially in the early
stages of the disease when the clinical manifestations
and laboratory tests may not allow us to correctly clas-
sify the patient. At such a stage, overdiagnosis may lead
to inappropriate treatment, while underdiagnosis may
delay the use of drugs able to control the disease.
Despite the great relevance of anti-dsDNA antibodies and
the technical progresses of the past years, the measurement
Fig. 3 Specificity of anti-DNA antibodies by inhibition ELISA. SLE serum A (a) or serum B (b) were incubated with 1:4 dilutions of the PK/H4 complex,
plasmid DNA (PK) or histone 5 (H4) peptide and then transferred to PK/H4 complex-coated plates. Results are expressed as percent inhibition of the
binding observed in the absence of inhibitors [100 – (OD of inhibitor/OD of buffer) × 100]. A higher inhibition is obtained with PK/H4 complexes in
the case of serum A, while in serum B complex or plasmid DNA pre-incubation results in identical inhibition. No inhibition is obtained with H4 peptide
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of these antibodies in clinical practice still represents a
challenge. The Farr assay is considered the gold standard in
anti-dsDNA detection because of its high specificity and
sensitivity and, mainly, for its high correlation with disease
activity. However, the use of radioactive material and the
short shelf life of radiolabeled DNA limits its use. CLIFT is
a very specific assay with a high predictive value for the
diagnosis of SLE, but is characterized by a low sensitivity
and is not very suitable for the follow-up of patients. A wide
number of solid phase assays have been developed, employ-
ing genomic or plasmid DNA in different assay formats,
and endowed with different sensitivity and specificity; how-
ever, their diagnostic performances are not always optimal.
It has been suggested that the ability of CLIFT to detect
SLE-specific anti-DNA antibodies may reside in the struc-
tural features of Crythidia DNA. Protozoan kinetoplast
DNA contains minicircles characterized by 18 runs of 4–6
adenine in 200 bp; each run contributes to the global
bending as the periodicity of the runs (1 every 10 bp) is in
phase with the helix periodicity [18]. DNA bending is
known to be related with nucleosome formation [32] and
the PK201/CAT plasmid has the highest efficiency of
interaction with core histones when compared with simi-
lar length plasmids not containing minicircles [33].
We thus selected the PK201/CAT plasmid and used it
as a probe to measure antibodies in sera. The plasmid
DNA on the solid phase allows us to detect anti-dsDNA
antibodies, but the assay specificity is unsatisfactory when
disease controls are taken into account. To better mimic
nucleosomal DNA, we analyzed the interaction of plasmid
DNA with basic peptides derived from histones.
Core histones possess very basic amino terminal regions
that interact with nucleosomal DNA. In the case of H4,
Fig. 4 Diagnostic properties of PK/H4 complexes: correlations with Aeskulisa anti-dsDNA assay, ECLAM, anti-C1q, and C3. The amount of IgG specific for
the PK/H4 complex are correlated with the level of anti-dsDNA antibodies detected by Aeskulisa (a), with the ECLAM score (b; r = 0.4094, p< 0.0001), and
with anti-C1q autoantibodies titers (c; r = 0.3106; p= 0.0176), and inversely correlated with complement C3 levels (d; r = –0.4196; p< 0.0001). C1q
complement component 1q, ECLAM European Consensus Lupus Activity Measurement, H4 histone 4, PK plasmid DNA
Table 2 Analysis of concordance between the different assays
for anti-dsDNA detection
Anti-H4/PK vs
Anti-dsDNA
Anti-H4/PK vs CLIF Anti-dsDNA vs CLIF
Concordance 0.684 0.643 0.611
Cohen K 0.317 0.314 0.289
Cohen K values: 0.21–0.40 indicates modest concordance; 0.41–0.60 indicates
moderate concordance; 0.61–0.80 indicates substantial concordance. CLIF
Crithidia Luciliae immunofluorescence, H4 histone 4, PK plasmid DNA
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the amino acid stretch involved in the interaction with the
double helix and responsible for DNA kinking is
represented by the highly charged sequence 16-23
[19]. X-ray crystallography of DNA complexes with
core histones at a resolution of 1.9 Angstrom depicts
with higher detail the interaction of H4 with DNA:
hydrogen bonds are formed between DNA and Q27,
T30, K31, P32, and R36 residues, while R17 and R19
associate with phosphate groups [20].
Among the H4 peptides we studied, only those contain-
ing the consensus sequence form a stable complex with
plasmid DNA. A sequence of similar charge from H2b
does not interact directly with DNA, according to crystal-
lographic studies [34], and was not able to retard the
migration of plasmid DNA.
The stable interaction of H4 peptide with plasmid DNA
has allowed us to build a simple and reliable assay that
does not require multistep procedures such as pre-coating
or DNA labeling, all potential sources of interferences.
By analyzing the epitopes expressed on the complex by
means of inhibition assays, we obtained direct evidence
for the existence of multiple epitopes, some residing on
the DNA moiety and some formed by the interaction of
DNA with the peptide. The assay can thus detect
autoantibodies binding either DNA or the DNA/peptide
complex. This ability to measure antibodies of different
specificity, including anti-dsDNA, is depicted by the good
correlation, but low concordance, with the “classical” as-
says for anti-dsDNA antibodies.
Combined with clinical and serological data, this assay
can contribute to a correct diagnosis and staging of SLE
patients. The high specificity of this test allows the differen-
tial diagnosis of SLE from other connective tissue disorders,
as only 5.9 % of disease control sera contain very low levels
of anti-PK/H4 antibodies. In the disease control group,
both rheumatoid factor-positive and -negative RA sera were
tested, thereby excluding any interference of rheumatoid
factors in the assay. It is also relevant that the group of
disease controls includes a high number of UCTD patients
that share clinical and serological manifestations with
definite connective tissue diseases but who do not fulfill
any of the existing classification criteria [26]. Thus, the
major novelty of the assay is its ability to discriminate
SLE from disorders that may clinically or serologically
resemble SLE.
The detection of anti-PK/H4 antibodies also gives reliable
information on disease activity, as indicated by the positive
correlation with the ECLAM score and the inverse correl-
ation with complement levels. Moreover, the level of anti-
PK/H4 antibodies is highly correlated with the level of anti-
C1q antibodies that are considered a reliable biomarker of
active disease, especially at the renal level [35–37].
As mentioned above, comparing the results obtained
with the CLIF test, anti-dsDNA Aeskulisa, and anti-PK/
H4, we observed a limited concordance, suggestive of the
presence in SLE sera of different populations of anti-DNA
antibodies which are differentially reactive in the different
assays. Similar observations have been previously reported
and led to the recommendation that more than one assay
should be used to better depict the repertoire of anti-
DNA present in a serum since no assay is able to detect
pathogenic antibodies only [9, 38]. When the presence
and amounts of anti-PK/H4 antibodies were related with
disease manifestations, we found that patients with
arthritis and active skin disease had higher levels of anti-
bodies. CLIFT is more often positive in patients with
active renal disease, as previously found [12–14], and
dsDNA detects antibodies in patients with skin or renal
involvement.
Conclusions
In conclusion, these clinico-serological correlations sug-
gest that different assays can detect anti-dsDNA anti-
bodies of different pathogenic potential. The PK/H4
complex may represent a novel tool to increase the
variety of autoantibodies that can be measured, comple-
menting the assays currently used for the detection of
anti-DNA antibodies.
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